跳至主要内容
临床试验/CTRI/2025/11/097363
CTRI/2025/11/097363尚未招募2 期

A randomised controlled trial to compare the efficacy of Tofacitinib versus Tofacitinib and Budesonide MMX for induction of clinical remission in moderate to severe Ulcerative Colitis

Postgraduate Institute of Medical Education and Research1 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2025年11月24日最近更新:

试验速览

阶段
2 期
状态
尚未招募
入组人数
50
试验地点
1
主要终点
Clinical remission

研究概览

简要总结

This is an open label, parallel group, randomised controlled trial to be conducted in India’s tertiary care centre, PGIMER, Chandigarh. This study evaluates the combined effectiveness of tofacitinib and budesonide MMX for the treatment of moderate to severe ulcerative colitis and compare it with tofacitinib.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
18.00 Year(s) 至 99.00 Year(s)(—)
性别
All

入选标准

  • Patients aged more than 18 years with moderate to severe ulcerative colitis, diagnosed by clinical, endoscopic and histologic criteria.

排除标准

  • Patients in remission,
  • Patients with ASUC defined as per the Truelove and Witt’s Criteria
  • Patients with disease limited to 15 cm from anal verge (proctitis only)
  • Patients with toxic megacolon
  • Patients with any serious infection, defined as any infection that requires hospitalization or change in the treatment plan
  • Patients with Indeterminate colitis or Crohn’s disease
  • Patients with prior history of exposure to tofacitinib
  • Patients with prior use of steroids in the last 3 months
  • Lactating and pregnant females
  • Patients with suspected or proven malignancy
  • Patients with dyslipidemia precluding the use of tofacitinib
  • Patients with severe comorbidities
  • Patients with diagnosed case of liver cirrhosis 14.

结局指标

主要结局

Clinical remission

时间窗: 12 weeks

次要结局

  • 1) Mucosal healing(2) Clinical response)

研究者

申办方类型
Government medical college
责任方
Principal Investigator
主要研究者

Dr Sayan Mazumder

Postgraduate Institute of Medical Education and Research

研究点 (1)

Loading locations...

相似试验

A study to compare the efficacy of Tofacitinib... | 临床试验